Kura Oncology, Inc.
BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE
Last updated:
Abstract:
The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
Status:
Application
Type:
Utility
Filling date:
13 Jul 2020
Issue date:
15 Apr 2021